kawasaki disease and immunizations

  1. kawasaki disease def
    acute systemic vasculitis of unknown origin, assoc w spring cleaning
  2. prevalence of kawa
    infants and young children (18mo-5 yrs is pk incidence)
  3. etiology of kawa
    • season-more common in winter or spring
    • possible infectious cause
    • race-originally found in asian pts but affects all
  4. clinical pres of kawa
    • fever, bilateral nonexudative conjunctivitis
    • erythema of lips and oral mucosa
    • changes in extremities
    • rash-usually on extre
    • cervical lyphadenopathy
  5. classical diag of kawa
    • fever for five or more days
    • four or more of the following (5):
    • changes in extrem
    • rash-skin peels off
    • conjunc
    • cracking of lips and oral cavity, strawberry tongue
    • cervical lymphadenopathy
  6. goals of acute tx of kawa
    • reducing inflamm of coronary artery wall
    • preventing coronary thrombosis
  7. goals of management long termkawa
    preventing myocardial ischemia and infarction in those that develop aneurysms, tx all w possible diag
  8. pharmacotherapy for kawa
    • IVIG-2gm/kg in a single inf(fever should come down rapidly)
    • asa-80-100mg/kg/d in 4 doses during acute , dec to 3-5 mg/kg/d until follow up shows no coronary artery changes at 6-8 wks after onset of illness
  9. complications of kawa
    coronary artery aneurysms primarily in untreated children
  10. Part A-national vaccine injury compensation Act
    provides details related to compensaion if injury occurs
  11. part B
    removes manufactureres from liability if injuries occur as long as full info regatding product is provided
  12. part C
    FDA must be notified within 7 days if an adverse rxn does occur
  13. documentation of vaccines
    manufacturer, lot, date of admin, name, address, title of person giving
Author
Ambestul
ID
13625
Card Set
kawasaki disease and immunizations
Description
kawa
Updated